Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol., 63, 2889, 10.1016/j.jacc.2013.11.002 Reiner, 2011, [ESC/EAS guidelines for the management of dyslipidaemias], Rev. Esp. Cardiol., 64, 1168.e1, 10.1016/j.recesp.2011.09.014 Thavendiranathan, 2006, Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials, Arch. Intern. Med., 166, 2307, 10.1001/archinte.166.21.2307 Cheung, 2004, Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes, Br. J. Clin. Pharmacol., 57, 640, 10.1111/j.1365-2125.2003.02060.x Cholesterol Treatment Trialists, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Cholesterol Treatment Trialists, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Cholesterol Treatment Trialists, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4 Bittner, 2015, Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the Medicare population 2007 to 2011, J. Am. Coll. Cardiol., 66, 1864, 10.1016/j.jacc.2015.08.042 Rosenson, 2015, Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease, J. Am. Coll. Cardiol., 65, 270, 10.1016/j.jacc.2014.09.088 Simons, 1996, Apparent discontinuation rates in patients prescribed lipid-lowering drugs, Med. J. Aust., 164, 208, 10.5694/j.1326-5377.1996.tb94138.x Avorn, 1998, Persistence of use of lipid-lowering medications: a cross-national study, JAMA, 279, 1458, 10.1001/jama.279.18.1458 Blackburn, 2005, Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study, Can. J. Cardiol., 21, 485 Schultz, 2005, Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population, Am. J. Manag. Care, 11, 306 Chapman, 2005, Predictors of adherence with antihypertensive and lipid-lowering therapy, Arch. Intern. Med., 165, 1147, 10.1001/archinte.165.10.1147 Svarstad, 1999, The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence, Patient Educ. Couns., 37, 113, 10.1016/S0738-3991(98)00107-4 McGinnis, 2007, Factors related to adherence to statin therapy, Ann. Pharmacother., 41, 1805, 10.1345/aph.1K209 Banach, 2015, Statin intolerance — an attempt at a unified definition. Position paper from an international lipid expert panel, Arch. Med. Sci., 11, 1, 10.5114/aoms.2015.49807 Stulc, 2015, Statin intolerance: the clinician's perspective, Curr. Atheroscler. Rep., 17, 69, 10.1007/s11883-015-0552-3 Jacobson, 2014, NLA task force on statin safety—2014 update, J. Clin. Lipidol., 8, S1, 10.1016/j.jacl.2014.03.003 Reiner, 2014, Resistance and intolerance to statins, Nutr. Metab. Cardiovasc. Dis., 24, 1057, 10.1016/j.numecd.2014.05.009 Fitchett, 2015, Cardiology patient page. Statin intolerance, Circulation, 131, e389, 10.1161/CIRCULATIONAHA.114.013189 Hovingh, 2016, Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey, Atherosclerosis, 245, 111, 10.1016/j.atherosclerosis.2015.12.015 Rasmussen, 2007, Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction, JAMA, 297, 177, 10.1001/jama.297.2.177 Bouchard, 2007, Impact of adherence to statins on coronary artery disease in primary prevention, Br. J. Clin. Pharmacol., 63, 698, 10.1111/j.1365-2125.2006.02828.x Mann, 2010, Predictors of nonadherence to statins: a systematic review and meta-analysis, Ann. Pharmacother., 44, 1410, 10.1345/aph.1P150 Henk, 2015, A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia, Adv. Ther., 32, 1104, 10.1007/s12325-015-0264-7 Toth, 2015, Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome, Evid. Based Med., 20, 176, 10.1136/ebmed-2015-110253 Gamboa, 2014, Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease, Am. J. Med. Sci., 348, 108, 10.1097/MAJ.0000000000000292 Reiner, 2016, Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries — findings from the EUROASPIRE IV survey, Atherosclerosis, 246, 243, 10.1016/j.atherosclerosis.2016.01.018 Lazaro, 2010, Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study, Rev. Esp. Cardiol., 63, 1428 Phillips, 2001, Clinical inertia, Ann. Intern. Med., 135, 825, 10.7326/0003-4819-135-9-200111060-00012 Okonofua, 2006, Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals, Hypertension, 47, 345, 10.1161/01.HYP.0000200702.76436.4b Shah, 2005, Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?, Diabetes Care, 28, 600, 10.2337/diacare.28.3.600 Aujoulat, 2015, Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium, BMC Fam. Pract., 16, 13, 10.1186/s12875-015-0221-1 Zafar, 2015, Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study, Diabet. Med., 32, 407, 10.1111/dme.12592 Krempf, 2015, Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey, Lipids Health Dis., 14, 45, 10.1186/s12944-015-0037-y Reiner, 2010, Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey, Atherosclerosis, 213, 598, 10.1016/j.atherosclerosis.2010.09.014 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur. Heart J., 36, 1012, 10.1093/eurheartj/ehv043 Fung, 2010, Patients' perspectives on nonadherence to statin therapy: a focus-group study, Perm. J., 14, 4, 10.7812/TPP/09-090 Kopecky, 2015, Insights into statin intolerance, Clin. Cardiol., 38, 520, 10.1002/clc.22432 Banach, 2015, Lipids, blood pressure and kidney update 2015, Lipids Health Dis., 14, 167, 10.1186/s12944-015-0169-0 Goldacre, 2014, Meta-analysis of side effects of statins shows need for trial transparency, BMJ, 348, g2940, 10.1136/bmj.g2940 Tobert, 2015, Statin tolerability: in defence of placebo-controlled trials, Eur. J. Prev. Cardiol. Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can. J. Cardiol., 29, 151, 10.1016/j.cjca.2012.11.032 Serban, 2016, A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations, Clin. Nutr., 35, 842, 10.1016/j.clnu.2015.09.007 Ursoniu, 2015, Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials, Arch. Med. Sci., 11, 253, 10.5114/aoms.2015.50960 Sahebkar, 2016, Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials, Nutrition, 32, 33, 10.1016/j.nut.2015.06.009 Arca, 2011, Treating statin-intolerant patients, Diabetes Metab. Syndr. Obes., 4, 155, 10.2147/DMSO.S11244 Perk, 2012, Atherosclerosis, 223, 1, 10.1016/j.atherosclerosis.2012.05.007 Krauss, 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment, Circulation, 117, 1537, 10.1161/CIRCULATIONAHA.107.708388 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Superko, 2012, Statins personalized, Med. Clin. N. Am., 96, 123, 10.1016/j.mcna.2011.11.004 Stone, 2012, Reducing residual risk in secondary prevention of cardiovascular disease, Circulation, 125, 1958, 10.1161/CIRCULATIONAHA.112.101782 Jackevicius, 2002, Adherence with statin therapy in elderly patients with and without acute coronary syndromes, JAMA, 288, 462, 10.1001/jama.288.4.462 Maningat, 2013, How do we improve patient compliance and adherence to long-term statin therapy?, Curr. Atheroscler. Rep., 15, 291, 10.1007/s11883-012-0291-7 Degli Esposti, 2012, Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis, Clin. Ther., 34, 190, 10.1016/j.clinthera.2011.12.011 Penning-van Beest, 2007, Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study, Eur. Heart J., 28, 154, 10.1093/eurheartj/ehl391 Chan, 2010, Patient, physician, and payment predictors of statin adherence, Med. Care, 48, 196, 10.1097/MLR.0b013e3181c132ad Brown, 2011, Medication adherence: WHO cares?, Mayo Clin. Proc., 86, 304, 10.4065/mcp.2010.0575 Markovic, 2005, Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service, Croat. Med. J., 46, 984 Jankowski, 2015, Secondary prevention of coronary artery disease in contemporary clinical practice, Cardiol. J., 22, 219, 10.5603/CJ.a2014.0066 Casebeer, 2009, Improving the physician–patient cardiovascular risk dialogue to improve statin adherence, BMC Fam. Pract., 10, 48, 10.1186/1471-2296-10-48 Izadpanah, 2015, The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects, Am. J. Phys. Cell Physiol., 309, C522, 10.1152/ajpcell.00406.2014 Banach, 2015, Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies, BMC Med., 13, 229, 10.1186/s12916-015-0459-4 Aranibar, 2011, Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling, Anal. Biochem., 410, 84, 10.1016/j.ab.2010.11.023 Skottheim, 2011, Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy, Mol. Diagn. Ther., 15, 221, 10.1007/BF03256413 Gee, 2015, Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity, Toxicology, 329, 40, 10.1016/j.tox.2015.01.005 Hinschberger, 2014, Immune-mediated necrotizing myopathy associated with antibodies to hydroxy-methyl-glutaryl-coenzyme A reductase, Rev. Med. Interne, 35, 546, 10.1016/j.revmed.2013.06.009 Toth, 2008, Clinical characterization and molecular mechanisms of statin myopathy, Expert. Rev. Cardiovasc. Ther., 6, 955, 10.1586/14779072.6.7.955 Hattori, 2009, Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment, J. Atheroscler. Thromb., 16, 870, 10.5551/jat.2048 Dube, 2014, CKM and LILRB5 are associated with serum levels of creatine kinase, Circ. Cardiovasc. Genet., 7, 880, 10.1161/CIRCGENETICS.113.000395 Cohen, 2012, Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users, J. Clin. Lipidol., 6, 208, 10.1016/j.jacl.2012.03.003 Wei, 2013, Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education, J. Clin. Lipidol., 7, 472, 10.1016/j.jacl.2013.03.001 Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — the PRIMO study, Cardiovasc. Drugs Ther., 19, 403, 10.1007/s10557-005-5686-z Parker, 2013, Effect of statins on skeletal muscle function, Circulation, 127, 96, 10.1161/CIRCULATIONAHA.112.136101 Bays, 2006, Statin safety: an overview and assessment of the data — 2005, Am. J. Cardiol., 97, 6C, 10.1016/j.amjcard.2005.12.006 Joy, 2009, Narrative review: statin-related myopathy, Ann. Intern. Med., 150, 858, 10.7326/0003-4819-150-12-200906160-00009 Grundy, 2002, Can statins cause chronic low-grade myopathy?, Ann. Intern. Med., 137, 617, 10.7326/0003-4819-137-7-200210010-00015 Jacobson, 2008, Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia, Mayo Clin. Proc., 83, 687, 10.1016/S0025-6196(11)60897-5 Bitzur, 2013, Intolerance to statins: mechanisms and management, Diabetes Care, 36, S325, 10.2337/dcS13-2038 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 McKenney, 2006, National Lipid Association Statin Safety Assessment Task F. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force, Am. J. Cardiol., 97, 89C, 10.1016/j.amjcard.2006.02.030 McFarland, 2014, Molecular mechanisms underlying the effects of statins in the central nervous system, Int. J. Mol. Sci., 15, 20607, 10.3390/ijms151120607 Singh-Manoux, 2012, Timing of onset of cognitive decline: results from Whitehall II prospective cohort study, BMJ, 344, d7622, 10.1136/bmj.d7622 Trompet, 2010, Pravastatin and cognitive function in the elderly. Results of the PROSPER study, J. Neurol., 257, 85, 10.1007/s00415-009-5271-7 Swiger, 2013, Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects, Mayo Clin. Proc., 88, 1213, 10.1016/j.mayocp.2013.07.013 Ott, 2015, Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials, J. Gen. Intern. Med., 30, 348, 10.1007/s11606-014-3115-3 Lakey, 2016, Statin intolerance in a referral lipid clinic, J. Clin. Lipidol, 10, 10.1016/j.jacl.2016.03.004 Sampson, 2012, Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges, Curr. Atheroscler. Rep., 14, 1, 10.1007/s11883-011-0219-7 Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 Group, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N. Engl. J. Med., 362, 1563, 10.1056/NEJMoa1001282 Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N. Engl. J. Med., 357, 2109, 10.1056/NEJMoa0706628 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N. Engl. J. Med., 367, 2089, 10.1056/NEJMoa1206797 Nicholls, 2015, Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial, Am. Heart J., 170, 1061, 10.1016/j.ahj.2015.09.007 Investigators, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N. Engl. J. Med., 365, 2255, 10.1056/NEJMoa1107579 Group, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N. Engl. J. Med., 371, 203, 10.1056/NEJMoa1300955 Katsiki, 2013, The role of fibrate treatment in dyslipidemia: an overview, Curr. Pharm. Des., 19, 3124, 10.2174/1381612811319170020 Chruschiel, 2015, Statins and fibrates: should they be recommended?, 11 Guyton, 2013, Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes), J. Am. Coll. Cardiol., 62, 1580, 10.1016/j.jacc.2013.07.023 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators, N. Engl. J. Med., 335, 1001, 10.1056/NEJM199610033351401 Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893 Boekholdt, 2014, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J. Am. Coll. Cardiol., 64, 485, 10.1016/j.jacc.2014.02.615 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N. Engl. J. Med., 372, 2387, 10.1056/NEJMoa1410489 Kastelein, 2014, Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies, Cardiovasc. Drugs Ther., 28, 281, 10.1007/s10557-014-6523-z Serban, 2016, Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options, Expert. Opin. Pharmacother., 17, 369, 10.1517/14656566.2016.1118055 Hassan, 2015, OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events, Glob. Cardiol. Sci. Pract., 2015, 20, 10.5339/gcsp.2015.20 Dragan, 2015, Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?, J. Cardiovasc. Pharmacol. Ther., 20, 157, 10.1177/1074248414539562 Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, N. Engl. J. Med., 372, 1500, 10.1056/NEJMoa1500858 Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N. Engl. J. Med., 372, 1489, 10.1056/NEJMoa1501031 Kereiakes, 2015, Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study, Am. Heart J., 169, 906, 10.1016/j.ahj.2015.03.004 Cannon, 2015, Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial, Eur. Heart J., 36, 1186, 10.1093/eurheartj/ehv028 Gencer, 2015, Sweetless'n low LDL-C targets for PCSK9 treatment, Eur. Heart J., 36, 1146, 10.1093/eurheartj/ehv056 Stoekenbroek, 2015, PCSK9 inhibition: the way forward in the treatment of dyslipidemia, BMC Med., 13, 258, 10.1186/s12916-015-0503-4 Chapman, 2015, PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era, Curr. Opin. Lipidol., 26, 511, 10.1097/MOL.0000000000000239 Zimmerman, 2015, How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control?, Am. Health Drug Benefits, 8, 436 Dadu, 2014, Lipid lowering with PCSK9 inhibitors, Nat. Rev. Cardiol., 11, 563, 10.1038/nrcardio.2014.84 Avis, 2010, Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia, J. Am. Coll. Cardiol., 55, 1121, 10.1016/j.jacc.2009.10.042 Nissen, 2016, Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial, JAMA, 10.1001/jama.2016.3608 Sattar, 2015, Efficacy and safety of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes Preiss, 2015, Should we worry about raised triglycerides: the controversy continues Sattar, 2015, Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4802 subjects with, at high risk for, or at low risk for, diabetes mellitus Colhoun, 2015, Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study Poirier, 2008, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2, J. Biol. Chem., 283, 2363, 10.1074/jbc.M708098200 Postmus, 2013, PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population, J. Lipid Res., 54, 561, 10.1194/jlr.M033969 Rader, 2014, Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, Circulation, 129, 1022, 10.1161/CIRCULATIONAHA.113.001292 Turner, 2015, Non-statin treatments for managing LDL cholesterol and their outcomes, Clin. Ther., 37, 2751, 10.1016/j.clinthera.2015.09.004 Nikolic, 2014, ETC-1002: a future option for lipid disorders?, Atherosclerosis, 237, 705, 10.1016/j.atherosclerosis.2014.10.099 Fernandez, 2008, Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports, Chest, 134, 824, 10.1378/chest.08-0943 Mlodinow, 2014, Statin adverse effects: sorting out the evidence, J. Fam. Pract., 63, 497 Zureik, 1996, Serum cholesterol concentration and death from suicide in men: Paris prospective study I, BMJ, 313, 649, 10.1136/bmj.313.7058.649 Olson, 2008, Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study, J. Women's Health (Larchmt), 17, 187, 10.1089/jwh.2007.0379 Kang, 2015, Statin use increases the risk of depressive disorder in stroke patients: a population-based study, J. Neurol. Sci., 348, 89, 10.1016/j.jns.2014.11.013 Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N. Engl. J. Med., 355, 549, 10.1056/NEJMoa061894 Golomb, 2004, Severe irritability associated with statin cholesterol-lowering drugs, QJM, 97, 229, 10.1093/qjmed/hch035 Tuccori, 2008, Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting, Drug Saf., 31, 1115, 10.2165/0002018-200831120-00007 Boriani, 2001, Nightmares and sleep disturbances with simvastatin and metoprolol, Ann. Pharmacother., 35, 1292, 10.1345/aph.10366 Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6 Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860 Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet, 380, 565, 10.1016/S0140-6736(12)61190-8 Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study, BMJ, 346, f2610, 10.1136/bmj.f2610 Bjornsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J. Hepatol., 56, 374, 10.1016/j.jhep.2011.07.023 Segal, 2002, Alopecia associated with atorvastatin, Am. J. Med., 113, 171, 10.1016/S0002-9343(02)01135-X Pua, 2006, Pravastatin-induced lichenoid drug eruption, Australas. J. Dermatol., 47, 57, 10.1111/j.1440-0960.2006.00225.x Adcock, 2001, Dermographism: an adverse effect of atorvastatin, J. Am. Board Fam. Pract., 14, 148 Anliker, 2002, Chronic urticaria to atorvastatin, Allergy, 57, 366, 10.1034/j.1398-9995.2002.1n3628.x Pfeiffer, 1998, Toxic epidermal necrolysis from atorvastatin, JAMA, 279, 1613, 10.1001/jama.279.20.1613-a Krasovec, 1993, Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors, Dermatology, 186, 248, 10.1159/000247363 Leuschen, 2013, Association of statin use with cataracts: a propensity score-matched analysis, JAMA Ophthalmol., 131, 1427, 10.1001/jamaophthalmol.2013.4575 Fraunfelder, 2008, Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use, Ophthalmology, 115, 2282, 10.1016/j.ophtha.2008.08.006 Athyros, 2004, Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Am. J. Kidney Dis., 43, 589, 10.1053/j.ajkd.2003.12.023 Hippisley-Cox, 2010, Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database, BMJ, 340, c2197, 10.1136/bmj.c2197 Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J. Am. Coll. Cardiol., 63, 2541, 10.1016/j.jacc.2014.03.019 Raal, 2015, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, Lancet, 385, 331, 10.1016/S0140-6736(14)61399-4 Raal, 2015, Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial, Lancet, 385, 341, 10.1016/S0140-6736(14)61374-X Blom, 2015, Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study, Circ. Res., 117, 731, 10.1161/CIRCRESAHA.115.307071 Robinson, 2014, Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial, JAMA, 311, 1870, 10.1001/jama.2014.4030 Koren, 2014, Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab, J. Am. Coll. Cardiol., 63, 2531, 10.1016/j.jacc.2014.03.018 Raal, 2015, Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorder (TAUSSIG) study. [Abstract No. 255] Kiyosue, 2016, A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk, Am. J. Cardiol., 117, 40, 10.1016/j.amjcard.2015.10.021 Kastelein, 2015, ODYSSEY FH I and FH II: 78week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur. Heart J., 36, 2996 Ginsberg, 2014, ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia, Circulation, 130, 2119 Bays, 2015, Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial, J. Clin. Endocrinol. Metab., 100, 3140, 10.1210/jc.2015-1520 Farnier, 2016, Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial, Atherosclerosis, 244, 138, 10.1016/j.atherosclerosis.2015.11.010 Moriarty, 2014, Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial, J. Clin. Lipidol., 8, 554, 10.1016/j.jacl.2014.09.007 Roth, 2015, Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [Abstract No. 0254] Stroes, 2015, Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [Abstract No. 0269]